explore -WSS

explore

author：knowledge 2025-09-29 16:25:32 - browse：859

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： AI can decode, harness the power of the humane immune system

WSS

Why age limits for politicians are a terrible idea

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Abridge raises $150m as clinical notes automation market heats up

MD Anderson's Padmanee Sharma responds to research credit suit

When women are denied an abortion, their children fare worse than peers

AI can decode, harness the power of the humane immune system

Wikipedia

explore

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare Advantage enrollment hits roughly 33.4 million

Heart attack and stroke risk calculators need revising

FDA warns medical device makers about rise in fabricated data

23andMe had bad news about my health. I wish a person had delivered it

The future of health care in the House

Apple is now the first public company to be valued at $3 trillion

New study raises questions about niacin and heart health

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

knowledge

Histogen: Failed biotech offers rare public look inside

Analysis of telehealth claims data suggest service duplication

Obamacare plans could cover weight loss drugs

Colorectal cancer study finds potential in overlooked immune cell

FDA authorizes Novavax’s updated Covid

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

hotspot

entertainment

focus

Wikipedia